## Takeda-sponsored symposium:

# RE-IMAGINING

# **TTP Management Goals**

**100 YEARS** FROM ITS DISCOVERY



Join our expert panel of speakers who will present the major scientific and medical advancements since the first identification of TTP 100 years ago, and explore the potential to redefine management goals to improve the long-term outcomes for patients with cTTP

Followed by a panel discussion and Q&A



### **ISTH 2024 Congress**



#### 12:15-12:30

Welcome and Introduction:
100 years since the first identification of TTP
Pantep Angchaisuksiri (Chair), Ramathibodi
Hospital of Mahidol University, Bangkok, Thailand



#### 12:30-12:45

Surviving or thriving: Redefining expectations Cristina Pascual Izquierdo, Hospital General Universitario Gregorio Marañón, Madrid, Spain



#### 12:45-13:00

Monitoring disease activity: A holistic approach to clinical outcomes and endpoints

Jerzy Windyga, Institute of Hematology and

Transfusion Medicine, Warsaw, Poland



#### 13:00-13:15

Changing the management landscape for patients with cTTP
Paul Coppo, Assistance Publique-Hôpitaux de Paris, Paris, France

cTTP, congenital thrombotic thrombocytopenic purpura; TTP, thrombotic thrombocytopenic purpura.

This ISTH-authorized symposium is initiated, organized, and funded by Takeda, and is intended only for healthcare professionals registered for the ISTH 2024 Congress. Treatment-related statements do not necessarily reflect Takeda's position nor are they necessarily in line with the approved labels in all countries. Some products mentioned are not registered or available for sale in Thailand. Please refer to the respective summary of product characteristic or treatment recommendation in your country. Copyright 2024. Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda logo are registered trademarks of Takeda Pharmaceutical Company Limited. VV-MEDMAT-99168 | April 2024